Prospective Assessment of Mood and Quality of Life in Cushing Syndrome Before and After Biochemical Control
The Journal of Clinical Endocrinology & Metabolism · 22.04.2026 · 111 (5) · e1396-e1411
DOI: 10.1210/clinem/dgaf598 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 31.10.2025. Verfasst von Angeliki Theodorou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. Hauptthemen laut MEDLINE: Quality of Life, Cushing Syndrome, Depression, Affect. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health/National Cancer Institute Cancer Center Support.
Abstract (Originalsprache)
Context
Cushing’s syndrome (CS) impairs quality of life (QoL) and mood. Prospective real-life data on posttreatment recovery and predictors of improvement are limited.
Objectives
Evaluate changes in QoL, depression, and anxiety in patients with CS, before and after biochemical control, and identify predictors of clinically meaningful improvement. Design and Setting Prospective observational study at a tertiary center. Patients Sixty-seven patients with endogenous CS (60 pituitary, 7 adrenal) were assessed with active disease and again after achieving biochemical control through surgery and/or medication. Outcomes Patient-reported outcomes included CushingQoL, Beck Depression Inventory-II (BDI-II), and State-Trait Anxiety Inventory (STAI).
Results
Mean and longest follow-up was 2.3 and 11.5 years, respectively. Treatment led to improvements in mean scores across all domains (QoL: +18.2 ± 20.9, BDI-II: −6.8 ± 8.6, STAI-State: −9.6 ± 12.5, STAI-Trait: −8.6 ± 12.6; all P < .001). However, a minimal important difference was achieved in 64.6% for QoL, 67.9% for BDI-II, and 53.2% and 52.8% for STAI subscales. After multivariable analysis, QoL improvements were predicted by lower baseline body mass index, pretreatment symptoms <3 years, postoperative hydrocortisone replacement >6 months, and normal follow-up late-night salivary cortisol (LNSC). Depression improvements were predicted by symptoms <3 years, normal follow-up LNSC, and surgical treatment. Anxiety improvements were predicted by younger age and >6 months postoperative hydrocortisone. Depression improved more gradually than QoL and anxiety.
Conclusion
Although effective treatment improves mood and QoL in CS, clinically meaningful recovery is variable and incomplete for some patients. Our findings highlight the need to limit diagnostic delay and provide comprehensive posttreatment care that includes normalization of cortisol circadian rhythm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
- Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
- Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
- Multidisciplinary Pituitary and Skull Base Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
ORCID-Profile: Angeliki Theodorou, Emily C Tan, Anne S Reiner, Marc A Cohen, Andrew L Lin, Viviane Tabar, Eliza B Geer
Förderung
- NCI NIH HHS
- National Institutes of Health/National Cancer Institute Cancer Center Support
Zitieren
APA
Theodorou, A., Tan, E. C., Bakkar, M. A., Reiner, A. S., Sazo, M., Cohen, M. A., Lin, A. L., Tabar, V., & Geer, E. B. (2026). Prospective Assessment of Mood and Quality of Life in Cushing Syndrome Before and After Biochemical Control. The Journal of Clinical Endocrinology & Metabolism, 111(5), e1396-e1411. https://doi.org/10.1210/clinem/dgaf598
Vancouver
Theodorou A, Tan EC, Bakkar MA, Reiner AS, Sazo M, Cohen MA, et al. Prospective Assessment of Mood and Quality of Life in Cushing Syndrome Before and After Biochemical Control. The Journal of Clinical Endocrinology & Metabolism. 2026;111(5):e1396-e1411. doi:10.1210/clinem/dgaf598
BibTeX
@article{Theodorou2026,
author = {Theodorou, Angeliki and Tan, Emily C and Bakkar, Mohammed A and Reiner, Anne S and Sazo, Maria and Cohen, Marc A and Lin, Andrew L and Tabar, Viviane and Geer, Eliza B},
title = {Prospective Assessment of Mood and Quality of Life in Cushing Syndrome Before and After Biochemical Control},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {5},
pages = {e1396--e1411},
doi = {10.1210/clinem/dgaf598}
}
EUVIMED